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Abstract
Summary Half of Métis citizens, compared to less than 10 %
of the general population of Ontario, reside in northern re-
gions, with little access to bone mineral density (BMD) test-
ing. Métis citizens had lower sex-specific and age-
standardized rates of BMD testing, yet similar rates of fracture
(both sexes) and pharmacotherapy (women only).
Purpose To examine osteoporosis management and common
osteoporosis-related fractures among Métis citizens compared
to the general population of older adults residing in Ontario.
Methods We linked healthcare (medical and pharmacy) utili-
zation and administrative (demographic) databases with the
Métis Nation of Ontario citizenship registry to estimate oste-
oporosis management (bone mineral density [BMD] testing,
pharmacotherapy) and fractures (hip, humerus, radius/ulna)
among adults aged ≥50 years, from April 1, 2006 to March
31, 2011. Pharmacotherapy data were limited to residents
aged ≥65 years. Sex-specific and age-standardized rates were
compared between the Métis and the general population. Mul-
tivariable logistic regression was used to compare rates of
BMD testing after controlling for differences in age and region
of residence between the Métis and the general population.
Results We studied 4219 Métis citizens (55 % men), and 140
(3%) experienced a fracture. Half of Métis citizens, compared
to less than 10 % of the general population of Ontario, resided
in northern regions. We identified significantly lower sex-
specific and age-standardized rates of BMD testing among
Métis compared to the general population, yet found little
difference in fracture rates (both sexes) or pharmacotherapy
(women only). Differences in BMD testing disappeared after
adjusting for region of residence among women yet remained
significant among men.
Conclusions Despite finding significantly lower rates of oste-
oporosis management among men, Métis men and women
were found to have similar age-standardized fracture rates to
the general population.
Keywords Aboriginal . Fracture . Management . Métis .
Osteoporosis . Pharmacotherapy
Introduction
The Canadian Constitution recognizes three groups of Ab-
original peoples: First Nations, Inuit, and Métis [1]. First Na-
tions people are those who identify as North American Indians
and are descendants of the original inhabitants of Canada [2].
The Inuit are Aboriginal peoples who mostly inhabit
Nunatsiavut (northern coastal Labrador), Nunavik (northern
Québec), the territory of Nunavut, and the Inuvialuit region
of the Northwest Territories [3]. The Métis are descendants of
unions between European men and First Nations women dur-
ing the early 17th century to late 19th century [4–6], develop-
ing a culture, history, and lifestyle distinct from First Nations
and Inuit people [5]. In 2011, 451,795 people identified as
Métis in Canada, representing 32 % of the total Aboriginal
R. Jandoc : S. M. Cadarette
Leslie Dan Faculty of Pharmacy, University of Toronto,
Toronto, ON, Canada
N. Jembere : S. Khan : S. M. Cadarette
Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
S. J. Russell :Y. Allard
Métis Nation of Ontario, Ottawa, ON, Canada
S. M. Cadarette (*)
Leslie L. Dan Pharmacy Building, University of Toronto, 144
College Street, Toronto, ON M5S 3M2, Canada
e-mail: s.cadarette@utoronto.ca
Arch Osteoporos (2015) 10: 12
DOI 10.1007/s11657-015-0212-9
population [3]. Despite their significant numbers, Métis are
either not identified specifically or are underrepresented in
Aboriginal health research [3, 5, 7, 8]. Most research has fo-
cused on First Nations; however, the Métis may differ in their
health behaviours and prevalence of risk factors and disease
and may require specific health interventions unique to their
culture. In addition, the Métis receive significantly fewer lo-
cal, provincial, and national resources for healthcare in com-
parison to First Nations and Inuit [9].
About one fifth (86,015 or 19 %) of all Métis reside in
Ontario, constituting the second largest provincial Métis pop-
ulation in Canada [3]. The Métis Nation of Ontario was
established in 1993 to address the needs of this large popula-
tion, and it continues to serve as the principal voice for the
Métis people in the province. One key contribution of the
Métis Nation of Ontario has involved establishing a voluntary
registry of Métis citizens residing in Ontario [10]. Data col-
lected and maintained by the Métis Nation of Ontario within
the provincial registry has permitted a closer examination of
key health challenges facing Métis people in Ontario.
In 2010, the Métis Nation of Ontario entered into a
partnership with the Public Health Agency of Canada
and the Institute for Clinical Evaluative Sciences to ex-
amine rates of selected chronic diseases among Métis.
Results have identified higher rates of cardiovascular dis-
ease [11], diabetes [12], and chronic obstructive pulmo-
nary disease [13] among Métis compared to the general
population of Ontario. The purpose of our study was to
compare rates of osteoporosis management and fractures
among Métis to the general population in Ontario.
Methods
Residents of all ages in Ontario have access to publicly
funded medical care and become eligible to receive phar-
macy benefits at the age of 65 years. We linked healthcare
(medical and pharmacy) utilization and administrative
(demographic) databases from the Ontario Ministry of
Health and Long-Term Care, housed at the Institute for
Clinical Evaluative Sciences, to the Métis Nation of On-
tario citizenship registry to compare osteoporosis manage-
ment and fracture rates between Métis citizens and the
general population.
Adults aged 50 or more years as of April 1, 2006 were
eligible. Ontario residents not registered with the Métis
Nation of Ontario were considered part of the general
population. We excluded individuals residing in long-
term care or whose last date of contact with the healthcare
system was before April 1, 2001. We therefore focused on
community-dwelling residents with some healthcare ser-
vices utilization within the past 5 years. Age, sex,
neighbourhood income, region of residence, and urban
status were determined as of April 1, 2006. Neighbourhood
income was based on census data and categorized into quin-
tiles ranked from poorest to wealthiest. Region of residence
was categorized into four main areas based on the number of
densitometers (bone mineral density [BMD] machines) [14,
15] and sample size of Métis in each of the province’s local
health integration networks: 1. Southwestern (moderate ac-
cess to densitometry), 2. Southcentral (high density of densi-
tometers and bone specialists, e.g. Hamilton and Toronto), 3.
Southeastern (moderate access to densitometry), and 4. North-
ern (few densitometers).
Urban residence was based on postal code and defined
according to the standard geographical classification def-
inition outlined by Statistics Canada: urban areas have a
population of at least 1000 and a population density of at
least 400 persons per square kilometre [16]. Fracture his-
tory (any of hip, humerus, or radius/ulna) within 6 months
prior to April 1, 2006 and osteoporosis management
(BMD testing and osteoporosis pharmacotherapy) within
1 year prior to April 1, 2006 were also summarized.
Osteoporosis pharmacotherapy was examined among resi-
dents aged 65 years or more and included bisphosphonates,
calcitonin, denosumab, and raloxifene. Teriparatide is not cov-
ered by the provincial drug plan [17, 18] and thus was not
considered.
Our main outcomes were 5-year rates of osteoporosis
management (BMD testing and pharmacotherapy [19])
and fracture (hip, humerus, radius/ulna, or any of these).
Given the known differences in osteoporosis fracture rates
by sex [20] and prior evidence of an inverted U-shape
between age and rates of BMD testing (rates peak among
those aged 60–69 years and are lower among those aged
younger than 60 and older than 69 years [14, 21]), results
were stratified by sex and age group.
Crude and age-standardized rates were reported per
10,000 persons. Age-standardized rates were calculated
using four age groups (50–64, 65–70, 70–74, and
≥75 years of age), by direct standardization according
to the 1991 Ontario census population with gamma dis-
tribution to estimate 95 % confidence intervals. The
direct standardization method permits the direct compar-
ison of rates between the Métis and the general popu-
lation since rates in both groups are standardized ac-
cording to the age distribution of the same referent
(standard) population [22]. Logistic regression was then
used to examine if Métis status was independently as-
sociated with BMD testing after adjusting for age, in-
come, region of residence, and urban status. Given that
neighbourhood income, region of residence, and urban
status are all based on postal code data, we also exam-
ined potential collinearity between the different possible
combinations of variables using chi-square contingency
tables.
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Results
We identified 4219 eligible Métis citizens and 3,822,661 eli-
gible persons from the general population of Ontario (Fig. 1).
Métis citizens were younger, had lower income status, and
fewer lived in urban areas (Table 1). Almost half of Métis
citizens, compared to less than 10 % of the general population
of Ontario, resided in northern regions, with little to no access
to BMD testing.
Osteoporosis management
The proportion of Ontario residents receiving BMD testing
was substantially lower among men (11 %) than among wom-
en (55 %). Although patterns of BMD testing were similar by
age group among persons of the same sex (Fig. 2), fewer
Métis citizens were tested after standardizing for age, Table 2.
Differences in BMD testing disappeared after adjusting for
neighbourhood income and region of residence among wom-
en, yet remained significant among men, Table 3. Métis men
also had lower rates of osteoporosis pharmacotherapy, even
after adjusting for age. In contrast, rates of osteoporosis phar-
macotherapy were similar among Métis women and the gen-
eral population.
Fracture rates
As expected, fracture rates increased with increasing age in
both sexes (Fig. 3) and were higher among women (from
2.9 % aged 50–54 to 12.0 % aged 75 and older) than among
men (from 1.5 % aged 50–54 to 5.4 % aged 75 and older).
Crude rates of hip fracture were significantly lower among
Métis women (15.2 per 10,000 persons, 95 % CI=8.3–25.4)
compared to women in the general population (35.7 per 10,
000 persons, 95 % CI=35.4–36.1), yet this difference disap-
peared after standardizing for age (Table 2). Similarly, we
identified little difference in all sex-specific fracture rates be-
tween Métis citizens and the general population after stan-
dardizing for age.
Discussion
We identified significantly lower sex-specific and age-
standardized rates of BMD testing among Métis compared
to the general population, yet found little difference in fracture
rates (both sexes) or pharmacotherapy (women only). Differ-
ences in BMD testing disappeared after adjusting for region of
residence among women, yet remained significant among
men.
Prior research identifies regional differences in BMD test-
ing for osteoporosis based on access to BMD testing sites
[23], which are largely located in urban centres [24, 25]. Giv-
en that half of Métis citizens, compared to less than 10 % of
the general population of Ontario, were found to reside in
northern regions with little access to BMD testing, it is not
surprising to find that crude as well as sex-specific and age-
standardized rates of BMD testing were lower among Métis
citizens compared to the general population. This is consistent
with prior research on other chronic conditions that has iden-
tified lower rates of screening and fewer specialist visits
among Métis that may relate to problems with access in re-
mote areas [11–13, 26–28]. Indeed, after adjusting for regional
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Non-Métis residents aged ≥50 
years and alive on April 1, 2006, 
N=4,102,721
• 1,934,766 men 
• 2,167,955 women 
Excluded, N=45
• Last contact >5 years, N=17




Métis residents aged ≥50 years 







Complete data for multivariable logistic regression, N=3,800,502
• 1,793,883 men
• 2,006,619 women
Fig. 1 Study flow diagram of the
Métis and the general population
inclusion. Missing data refers to
missing information regarding
neighbourhood income, region of
residence, and “urban” status
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Table 1 Characteristics of the Métis and the general population, 1 April 2006
Characteristic Men Women
Métis General Métis General
N=2321 N=1,804,959 N=1898 N=2,017,702
Median age, years (IQR) 59 (53–66) 61 (55–70) 59 (54–67) 62 (55–72)
Mean age, years (SD) 60.2 (8.2) 63.0 (10.0) 60.8 (8.7) 64.4 (10.9)
Age in years (%)
50–54 30.9 24.3 30.5 22.3
55–59 23.6 21.5 21.7 19.8
60–64 17.3 15.8 17.5 14.7
65–69 13.2 12.4 12.5 12.0
70–74 8.7 10.3 9.1 10.5
≥75 6.3 15.7 8.6 20.7
Neighbourhood income quintile (%)a
1 (lowest income) 23.5 18.1 23.5 19.3
2 20.7 19.9 21.6 20.4
3 21.4 19.5 19.3 19.4
4 17.7 20.4 18.8 19.8
5 (highest income) 16.7 22.2 16.8 21.1
Region of residence (%)a
Southwestern 7.1 18.3 7.9 18.3
Erie St. Clair 2.4 5.4 2.1 5.3
South West 3.5 7.8 3.6 7.9
Waterloo Wellington 1.2 5.1 2.2 5.1
Southcentral 9.2 44.7 13.5 45.0
Hamilton Niagara Haldimand Brant 4.0 11.6 6.9 11.8
Central West 0.9 5.0 1.0 4.8
Mississauga Halton 1.1 7.6 1.9 7.5
Toronto Central 1.5 8.5 1.8 8.8
Central 1.7 11.9 2.0 12.1
Southeastern 33.0 29.5 34.6 29.6
Central East 4.7 11.8 4.6 11.9
South East 3.6 4.5 2.4 4.5
Champlain 4.5 9.5 4.8 9.6
North Simcoe Muskoka 20.3 3.7 22.8 3.6
Northern 50.6 7.5 44.0 7.1
North East 36.1 5.4 29.4 5.2
North West 14.5 2.1 14.6 1.9
Urban residence (%)a 62.4 85.5 68.3 86.6
Fracture historyb 0.1 0.3 0.7 0.6
Osteoporosis managementc
Bone mineral density test 1.5 2.5 16.4 19.5
Pharmacotherapy (aged ≥65)d 1.7 4.1 22.6 26.3
a Proportions adjusted for missing data for neighbourhood income (1 %Métis and 0.7 % general population) and region (0.5 %Métis and 0.4 % general
population)
b Hip, humerus, or radius/ulna fracture within 6 months prior to April 1, 2006
c 1 year lookback from April 1, 2006 (April 1, 2005 to March 31, 2006)
d Osteoporosis pharmacotherapy includes bisphosphonates, calcitonin, denosumab, and raloxifene
































































Fig. 2 Five-year bone mineral density (BMD) testing rates among the Métis (closed circle) and the general population (open square), by age group,
stratified by sex. 95 % confidence intervals for Métis estimates are wide and overlap with the general population in all comparisons
Table 2 Five-year ratesa of osteoporosis management and fractures in the Métis and the general population of Ontario
Outcome of interest Men Women
Métis General population Métis General population
N=2321 N=180,959 N=1898 N=2,017,702
Osteoporosis management
1. Bone mineral density test
N 136 197,730 923 1,102,997
Crude rate (95 % CI) 122.4 (102.8–144.7) 230.1 (229.1–231.1) 999.1 (935.7–1065.7) 1137.1 (1134.9–1139.2)
Age-standardized rate (95 % CI) 134.2 (110.9–160.9) 245.5 (244.4–246.6)* 969.1 (889.3–1054.1) 1135.1 (1132.9–1137.3)*
2. Osteoporosis pharmacotherapy (aged ≥65)b
N 35 63,205 203 345,213
Crude rate (95 % CI) 114.1 (79.5–158.6) 201.4 (199.8–203.0) 751.2 (651.4–861.9) 855.7 (852.8–858.5)
Age-standardized rate (95 % CI) 125.5 (82.8–182.4) 198.7 (197.0–200.4)* 758.4 (626.3–910.1) 850.9 (847.9–854.0)
3. Osteoporosis management (BMD test or pharmacotherapy)b
N 150 219,668 993 1,201,199
Crude rate (95 % CI) 134.9 (114.2–158.2) 255.6 (254.5–256.7) 1074.9 (1009.1–1143.9) 1238.4 (1236.2–1240.6)
Age-standardized rate (95 % CI) 161.3 (133.4–193.2) 274.6 (273.4–275.8)* 1093.2 (1007.6–1184.0) 1254.3 (1251.9–1256.6)*
Fractures
1. Hip fracture
N 16 14,670 14 34,675
Crude rate (95 % CI) 14.3 (8.2–23.2) 17.1 (16.8–17.4) 15.2 (8.3–25.4) 35.7 (35.4–36.1)
Age-standardized rate (95 % CI) 24.7 (11.7–46.0) 18.8 (18.4–19.1) 26.7 (13.3–47.9) 41.1 (40.5–41.6)
2. Humerus fracture
N 12 11,278 22 30,070
Crude rate (95 % CI) 10.7 (5.5–18.7) 13.1 (12.9–13.4) 23.8 (14.9–36.1) 31.0 (30.7–31.4)
Age-standardized rate (95 % CI) 13.5 (5.9–26.3) 13.7 (13.4–14.0) 25.2 (14.9–40.0) 33.4 (33.0–33.9)
3. Radius or ulna fracture
N 21 20,452 65 63,796
Crude rate (95 % CI) 18.8 (11.6–28.7) 23.8 (23.5–24.1) 70.4 (54.3–89.7) 65.8 (65.3–66.3)
Age-standardized rate (95 % CI) 19.2 (11.2–30.7) 24.1 (23.7–24.4) 77.8 (57.6–102.7) 68.2 (67.6–68.7)
4. Any fracture (hip, humerus, radius/ulna)
N 45 43,132 95 116,539
Crude rate (95 % CI) 40.2 (29.3–53.8) 50.2 (49.7–50.7) 102.8 (83.2–125.7) 120.1 (119.4–120.8)
Age-standardized rate (95 % CI) 53.8 (35.8–77.8) 52.5 (52.0–53.1) 122.5 (95.8–154.4) 128.9 (128.1–129.8)
*Differences in age-standardized rates are statistically significant, p<0.05
a Rates per 10,000 people; age-standardized using sex-specific direct standardization to the 1991 Canadian population
bOsteoporosis pharmacotherapy includes bisphosphonates, calcitonin, denosumab, and raloxifene
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quintile), differences in rates of BMD testing disappeared
among women. However, differences persisted among men.
Prior research identifies higher rates of osteoporosis risk fac-
tors such as cardiovascular disease, chronic obstructive pul-
monary disease, and diabetes among Métis compared to the
general population of Ontario [11–13], and thus, the finding
that BMD testing rates were lower among Métis men after
adjusting for regional characteristics is puzzling. Indeed, our
finding that Métis men had lower age-standardized rates of
osteoporosis pharmacotherapy suggests a potential gender
gap. Prior research identifies a tight link between BMD testing
and osteoporosis treatment initiation [25]. It is thus not sur-
prising to find that lower rates of BMD testing among men
would translate into lower rates of pharmacoprevention. Prior
Table 3 Odds ratio estimates for bone mineral density (BMD) testing among Métis vs. general population of Ontario by sex; unadjusted and adjusted
for age, income, and region of residence
Characteristic Men Women
Unadjusted Adjusted Unadjusted Adjusted
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
N=1,793,883 N=1,793,883 N=2,006,619 N=2,006,619
Métis citizen 0.51 (0.43–0.61) 0.82 (0.69–0.98) 0.78 (0.71–0.86) 0.95 (0.87–1.04)
Age in years
50–54 1 1 1 1
55–59 1.60 (1.57–1.63) 1.61 (1.58–1.64) 1.31 (1.30–1.33) 1.33 (1.32–1.34)
60–64 2.97 (2.91–3.02) 3.03 (2.98–3.08) 1.53 (1.51–1.54) 1.57 (1.56–1.59)
65–69 4.15 (4.08–4.23) 4.26 (4.19–4.34) 1.43 (1.42–1.44) 1.48 (1.46–1.50)
70–74 4.56 (4.48–4.65) 4.69 (4.60–4.77) 1.12 (1.11–1.13) 1.16 (1.15–1.17)
≥75 3.84 (3.77–3.91) 3.91 (3.84–3.98) 0.50 (0.49–0.50) 0.51 (0.50–0.51)
Neighbourhood income quintile
1 (lowest income) 1 1 1 1
2 1.05 (1.04–1.07) 1.03 (1.02–1.05) 1.17 (1.16–1.18) 1.14 (1.13–1.15)
3 1.04 (1.02–1.06) 1.05 (1.03–1.06) 1.27 (1.26–1.28) 1.23 (1.22–1.24)
4 1.06 (1.04–1.07) 1.06 (1.04–1.07) 1.41 (1.39–1.42) 1.32 (1.31–1.33)
5 (highest income) 1.11 (1.10–1.13) 1.10 (1.09–1.12) 1.58 (1.57–1.60) 1.47 (1.46–1.49)
Region of residence
Southwesterna
Erie St. Clair 1 1 1 1
South West 1.30 (1.26–1.35) 1.36 (1.32–1.41) 1.07 (1.06–1.09) 1.11 (1.09–1.12)
Waterloo Wellington 1.72 (1.66–1.78) 1.79 (1.73–1.85) 1.52 (1.49–1.54) 1.53 (1.50–1.55)
Southcentrala
Hamilton Niagara Haldimand Brant 2.31 (2.24–2.38) 2.29 (2.23–2.36) 1.80 (1.77–1.82) 1.85 (1.82–1.88)
Central West 1.93 (1.87–2.00) 2.04 (1.97–2.11) 1.78 (1.75–1.81) 1.73 (1.70–1.76)
Mississauga Halton 2.08 (2.02–2.15) 2.17 (2.11–2.24) 2.30 (2.27–2.34) 2.19 (2.16–2.23)
Toronto Central 2.43 (2.36–2.51) 2.51 (2.43–2.59) 1.87 (1.84–1.90) 1.91 (1.88–1.94)
Central 2.66 (2.58–2.73) 2.71 (2.63–2.79) 2.21 (2.17–2.34) 2.18 (2.15–2.22)
Southeasterna
Central East 2.16 (2.10–2.23) 2.23 (2.16–2.29) 1.75 (1.73–1.78) 1.81 (1.78–1.84)
South East 1.49 (1.44–1.55) 1.54 (1.49–1.60) 1.17 (1.15–1.19) 1.23 (1.21–1.25)
Champlain 1.65 (1.60–1.70) 1.73 (1.68–1.78) 1.62 (1.60–1.65) 1.63 (1.61–1.66)
North Simcoe Muskoka 1.46 (1.41–1.52) 1.52 (1.46–1.58) 1.56 (1.53–1.59) 1.61 (1.57–1.64)
Northerna
North East 1.17 (1.13–1.22) 1.22 (1.18–1.26) 0.93 (0.91–0.95) 0.95 (0.93–0.97)
North West 0.58 (0.55–0.62) 0.62 (0.58–0.66) 0.72 (0.71–0.74) 0.73 (0.71–0.75)
Urban residence 1.51 (1.49–1.53) 1.18 (1.16–1.20) 1.41 (1.40–1.42) 1.11 (1.10–1.12)
a Region of residence was categorized into four main areas based on the number of densitometers (BMDmachines) [14, 15] and sample size of Métis in
each of the province’s local health integration networks: Southwestern (moderate access to densitometry), Southcentral (high density of densitometers
and bone specialists, e.g. Hamilton and Toronto), Southeastern (moderate access to densitometry), and Northern (few densitometers)
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research has also found that men have lower rates of post-
fracture treatment and glucocorticoid-induced osteoporosis
management compared to women [29, 30]. It is thus particu-
larly interesting to find that Métis men have lower rates of
BMD testing after adjusting for regional differences in access,
compared with men in the general population. Further re-
search to better understand the reasons for lower rates of
BMD testing and osteoporosis treatment among Métis men
compared to the general population of men is of interest.
Access to BMD testing has been shown to impact pharma-
cotherapy [25] and thus is proposed to lead to potential ineq-
uities in fracture prevention. One interpretation of our findings
may therefore be to improve access to BMD testing in north-
ern and rural areas of Ontario. However, despite finding lower
age-adjusted rates of BMD testing (both sexes) and pharma-
cotherapy (men only) among Métis citizens compared to the
general population, fracture rates were found to be similar.
Although this finding is comforting, our results are limited
by not including vertebral fractures. Vertebral fractures are
the most common type of osteoporotic fracture and cause
significant morbidity [20]; however, less than half come to
clinical attention [31, 32]. For this reason, healthcare admin-
istrative data are limited in ability to capture vertebral frac-
tures. It is thus possible that a closer examination with X-rays
could identify significant differences in vertebral fractures and
thus osteoporosis morbidity, particularly among Métis men.
Nonetheless, our finding of little difference in fracture rates
between the Métis population and general population of On-
tario is consistent with prior research that found similar prev-
alence of osteoporosis or fracture among Métis and all other
residents in Manitoba [33]. However, our results contradict
findings from research conducted with larger groups of Ab-
original peoples in Manitoba that document significantly
higher fracture rates among First Nations after adjusting for
age, sex, income, and geographical residence area [34]. Both
studies from Manitoba included vertebral fractures, and dif-
ferences in vertebral fractures among First Nations were large-
ly identified in younger age groups compared to our study that
focused on adults aged 50 or more years [34]. Higher fracture
rates among First Nations people in Manitoba are proposed
to be related to higher prevalence of diabetes, comorbid-
ity, and substance abuse [35] and a higher rate of acciden-
tal and non-accidental trauma [34]. Further research into
the burden of osteoporosis among distinct groups of Ab-
original peoples (First Nations, Inuit, and Métis) is of
interest. Results from Manitoba identified that First Na-
tions people are less likely to receive a BMD test or phar-
macotherapy within 6 months post-fracture [36], yet are at
higher risk for post-fracture mortality [37]. Due to the
small number of Métis citizens with fractures in our study,
we were unable to examine post-fracture osteoporosis
management or adherence to therapy.
We acknowledge that our study is subject to some limita-
tions. First, given that the Métis citizenship registry is volun-
tary and requires individuals to provide proof of ancestry, it
may not capture the entire Métis population in Ontario and
thus misclassify some Métis in the general population. In
comparison to the 2011 National Household Survey, our co-
hort of Métis citizens represents approximately 25 % of the
equivalently agedMétis in Ontario and is represented by more
men (55 vs. 49 % in the National Household Survey) [3].
Registration with the Métis Nation of Ontario permits citizens
to apply for Harvesters Certification that allows holders to
hunt and fish [38], a benefit that may be more appealing to
male Métis. Nonetheless, by completing analyses separately
for men and women and standardizing by age, we were able to
adjust for any sex- and age-related differences. In addition,
although Métis people not registered with the Métis Nation
of Ontario, as well as other Aboriginal peoples (First Nations
and Inuit), would be included with the general population es-
timates, we anticipate little overall impact on estimates of
osteoporosis management in the general population since the-
se Aboriginal groups are few in number compared to the large
population of older adults in Ontario. Second, the Ontario
DrugBenefit database is limited to individuals aged ≥65 years,
and thus, we did not have pharmacy data for younger patients.
Although we could have restricted our study to persons aged





































































Fig. 3 Five-year fracture rates among the Métis (closed circle) and the
general population (open square), by age group, stratified by sex. Any
fracture refers to a fracture of the hip, humerus, or radius/ulna. The 95 %
confidence intervals for Métis estimates are wide and overlap with the
general population in all comparisons
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in our study permitted a more comprehensive comparison of
BMD testing and fracture rates. Third, our study was limited
by a relatively small sample size of Métis men and women
aged 50 or more years, with few overall fractures, and wewere
unable to examine other osteoporosis risk factors, such as
glucocorticoid exposure that may differentially impact osteo-
porosis management in the Métis and the general population.
Finally, our data did not capture vertebral fractures, and thus,
we may underestimate differences in rates of some osteopo-
rotic fractures between Métis citizens and the general popula-
tion. Despite these limitations, we have significant strength in
our ability to leverage data for the province of Ontario and in
working with the Métis Nation of Ontario and the Public
Health Agency of Ontario in their efforts to better understand
Métis health.
As the Métis Nation of Ontario registry and other Métis
registries grow across Canada, future research may be able
to examine comparative rates of osteoporosis management
and fractures in a larger and more representative sample of
Métis citizens, and in particular, post-fracture osteoporosis
management. We recommend that future research aim to clar-
ify the burden of osteoporosis management among different
Aboriginal groups, particularly among men; and examine
whether regional variation in access to services, such as
BMD testing in rural and remote locations, translate into im-
portant differences in post-fracture management and adher-
ence to osteoporosis pharmacotherapy.
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